Recruiting × Leukemia, Lymphocytic, Chronic, B-Cell × 90 days × Clear all Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Phase 1/2 Recruiting
146 enrolled
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 4 Recruiting
150 enrolled
ALICIA(BY)
Recruiting
50 enrolled
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
Recruiting
135 enrolled
AQUALIS
Recruiting
120 enrolled
CaDAnCe-302
Phase 3 Recruiting
250 enrolled
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Phase 3 Recruiting
247 enrolled
OPAL
Phase 1/2 Recruiting
144 enrolled
CaDAnCe-101
Phase 1/2 Recruiting
614 enrolled
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Phase 3 Recruiting
630 enrolled
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 3 Recruiting
500 enrolled
REBELLE
Phase NA Recruiting
60 enrolled
Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia
Phase 1 Recruiting
24 enrolled
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Phase 3 Recruiting
500 enrolled
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Recruiting
1,000 enrolled
Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2 Recruiting
168 enrolled
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Phase 1 Recruiting
572 enrolled
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Phase 2 Recruiting
100 enrolled
CAN3001
Phase 3 Recruiting
700 enrolled
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
Recruiting
2,000 enrolled
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
Phase 2 Recruiting
40 enrolled
EXCELL
Phase 3 Recruiting
386 enrolled
TAILOR
Phase 2 Recruiting
320 enrolled
PROVIDENCE
Recruiting
132 enrolled
BELLWAVE-011
Phase 3 Recruiting
1,200 enrolled
QOLIBRI
Recruiting
180 enrolled
Soundtrack-E
Phase 1/2 Recruiting
408 enrolled
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
Phase 2 Recruiting
20 enrolled
Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial
Phase 2 Recruiting
61 enrolled
The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients
Phase NA Recruiting
70 enrolled
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Phase 3 Recruiting
170 enrolled
Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
Recruiting
1,263 enrolled
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Recruiting
2,000 enrolled
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Phase 1 Recruiting
137 enrolled
BRUIN-CLL-314
Phase 3 Recruiting
662 enrolled
Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma
Recruiting
100 enrolled
Hematopoiesis in MBL and CLL Versus Healthy Age-Matched Control Subjects
Recruiting
50 enrolled
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Phase 1/2 Recruiting
32 enrolled
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Phase 2 Recruiting
108 enrolled
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
Phase 2 Recruiting
230 enrolled
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
Phase 2 Recruiting
75 enrolled
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
Phase 1/2 Recruiting
27 enrolled
TITANium
Phase 1/2 Recruiting
174 enrolled
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
Phase 1 Recruiting
46 enrolled
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
Phase 3 Recruiting
250 enrolled
Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2 Recruiting
27 enrolled
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 2 Recruiting
249 enrolled
Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
Phase 2 Recruiting
32 enrolled
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Phase 1 Recruiting
248 enrolled
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Phase 1/2 Recruiting
160 enrolled